{'fraction_non_alphanumeric': 0.02481902792140641, 'fraction_numerical': 0.009307135470527405, 'mean_word_length': 5.453333333333333, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Interaction of albumin and vincristine with a human lymphoblastic leukemia cell line in vitro.

To investigate the potential influence of albumin on the antitumor effect of vincristine (VCR), cells from a human lymphoblastic leukemia cell line (CEM) were exposed in vitro to albumin and a clinically attainable VCR concentration (10(-7)M). Increasing concentrations of albumin between 1 and 4 g/100 ml resulted in a corresponding reduction of VCR-induced growth suppression. Studies employing tritiated vincristine ([3H]-VCR) revealed a progressive inhibition of uptake of the radio-label into CEM cells with increasing concentrations of albumin. These in vitro data show a previously unrecognized protective effect of increasing concentrations of albumin on the growth of human lymphoblastic leukemia cells exposed to VCR as a consequence of inhibition of drug uptake. Further in vivo pharmacologic studies will be necessary to determine their clinical significance.